시장보고서
상품코드
1271151

알레르기성 결막염(AC) 시장 : 시판 및 파이프라인 의약품 평가, 임상시험, 경쟁 구도

Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

발행일: | 리서치사: GlobalData | 페이지 정보: 영문 74 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

이 보고서는 알레르기성 결막염(AC) 시장에서 시판 중인 의약품과 파이프라인 의약품의 임상시험 동향, 경쟁 구도에 대한 데이터 기반 개요를 제공합니다.

목차

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

  • 질병 개요
  • 역학 개요
  • 치료 개요

제4장 출시 약제 평가

  • 주요 출시 약제
  • 작용기전별 개요
  • 투여 경로별 개요
  • 출시된 약제 개요와 판매 예측

제5장 가격 결정과 상환 평가

  • 연간 치료비
  • 약가 설정과 상환까지 시간

제6장 파이프라인 의약품 평가

  • 제Ⅲ상 파이프라인 의약품
  • 개발 단계별 개요
  • 분자 유형별 개요
  • 작용기전별 개요
  • 투여 경로별 개요
  • 약제 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
  • 치료 영역 및 적응증 고유의 PTSR 및 LoA

제7장 임상시험 평가

  • 역사적 개요
  • 상별 개요
  • 현황별 개요
  • 진행중 및 계획중인 임상시험에 관한 상별 개요
  • 가상 컴포넌트를 사용한 임상시험
  • 지역별 개요
  • 단일국 및 다국적 임상시험, 지역별
  • 주요 스폰서 20개사와 내역, 상별
  • 주요 스폰서 20개사와 내역, 현황별
  • 엔드포인트 현황별 개요
  • 인종 및 민족별 개요
  • 등록 데이터
  • 임상시험 사이트 상위 20개국
  • 세계의 주요 20개 사이트
  • 실현 가능성 분석 - 지역별 개요
  • 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

  • 지역별 합병, 인수, 전략적 제휴
  • 최근의 합병, 인수, 전략적 제휴

제9장 상업적 평가

  • 주요 시장 진출기업

제10장 향후의 시장 성장 촉진요인

제11장 부록

LSH 23.05.22

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in AC therapeutics.

There will be more than 1 billion prevalent cases of AC in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for AC.

The innovator marketed drugs space for AC mainly consists of dual-acting antihistamines and mast cell inhibitors.

R&D activity in AC is promising with four drugs in Phase III and 10 drugs in Phase II of development.

Clinical trial space in AC mainly includes commercial sponsors, with the US emerging as the key country for conducting Phase III trials.

Two strategic alliances and one merger & acquisition involving companies developing AC assets were successfully completed in the past two years.

Scope

GlobalData's Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the AC market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

  • 5.1 Annual Therapy Cost
  • 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

  • 6.1 Phase III Pipeline Drugs
  • 6.2 Overview by Development Stage
  • 6.3 Overview by Molecule Type
  • 6.4 Overview by Mechanism of Action
  • 6.5 Overview by Route of Administration
  • 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

  • 7.1 Historical Overview
  • 7.2 Overview by Phase
  • 7.3 Overview by Status
  • 7.4 Overview by Phase for Ongoing and Planned Trials
  • 7.5 Trials with Virtual Components
  • 7.6 Geographic Overview
  • 7.7 Single-Country and Multinational Trials by Region
  • 7.8 Top 20 Sponsors with Breakdown by Phase
  • 7.9 Top 20 Sponsors with Breakdown by Status
  • 7.10 Overview by Endpoint Status
  • 7.11 Overview by Race and Ethnicity
  • 7.12 Enrollment Data
  • 7.13 Top 20 countries for Trial Sites
  • 7.14 Top 20 Sites Globally
  • 7.15 Feasibility Analysis - Geographic Overview
  • 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

  • 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

  • 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

  • 11.1 Methodology
  • 11.2 Methodology - Sales Forecast
  • 11.3 Methodology - Pricing and Reimbursement
  • 11.4 Methodology - PTSR and LoA Analysis
  • 11.5 About the Authors
  • 11.6 Contact Us
  • 11.7 Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제